Asset Details
Do you wish to reserve the book?
c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
Do you wish to request the book?
c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
2016
Overview
In this study, we investigated the therapeutic effects of c-MET inhibition in ovarian clear cell carcinoma (OCCC). Expression levels of c-MET in the epithelial ovarian cancers (EOCs) and normal ovarian tissues were evaluated using real-time PCR. To test the effects of c-MET inhibitors in OCCC cell lines, we performed MTT and apoptosis assays. We used Western blots to evaluate the expression of c-MET and its down-stream pathway.
In vivo
experiments were performed to test the effects of c-MET inhibitor on tumor growth in orthotopic mouse xenografts of OCCC cell line RMG1 and a patient-derived tumor xenograft (PDX) model of OCCC. c-MET expression was significantly greater in OCCCs compared with serous carcinomas and normal ovarian tissues (p < 0.001). In
in vitro
study, inhibition of c-MET using c-MET inhibitors (SU11274 or crizotinib) significantly decreased the proliferation, and increased the apoptosis of OCCC cells. SU11274 decreased expression of the p-c-MET proteins and blocked the phosphorylation of down-stream proteins Akt and Erk. Furthermore, SU11274 treatment significantly decreased the
in vivo
tumor weight in xenograft models of RMG1 cell and a PDX model for OCCC compared to control (p = 0.004 and p = 0.009, respectively).
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 64
/ 82
/ Adenocarcinoma, Clear Cell - drug therapy
/ Adenocarcinoma, Clear Cell - genetics
/ Adenocarcinoma, Clear Cell - metabolism
/ Adenocarcinoma, Clear Cell - pathology
/ Animals
/ Cell Proliferation - drug effects
/ Cell Survival - drug effects
/ Female
/ Gene Expression Regulation, Neoplastic
/ Humanities and Social Sciences
/ Humans
/ Neoplasm Proteins - genetics
/ Neoplasm Proteins - metabolism
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - genetics
/ Ovarian Neoplasms - metabolism
/ Ovarian Neoplasms - pathology
/ Phosphorylation - drug effects
/ Piperazines - therapeutic use
/ Proto-Oncogene Proteins c-met - metabolism
/ Science
/ Signal Transduction - drug effects
/ Sulfonamides - therapeutic use
